Stay updated on Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the dosage of Pembrolizumab (MK3475) to 200mg every three weeks in the clinical trial for poorly chemo-responsive thyroid and salivary gland tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:29.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the health conditions and prior treatments required for inclusion in the study. Previously, this section only indicated that no information was provided.
    Difference
    54%
    Check dated 2024-05-22T21:00:11.000Z thumbnail image
  7. Check
    19 days ago
    Change Detected
    Summary
    The value on the webpage related to the study record 'Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors (iPRIME)' has been updated from 2023 02 16 to 2024 05 21. This change likely indicates a shift in the estimated study completion date from February 16, 2023, to May 21, 2024, with the note 'Estimated' added to the new date.
    Difference
    1.0%
    Check dated 2024-05-21T14:32:57.000Z thumbnail image
  8. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:35:04.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Chemo-Resistant Tumors Clinical Trial page.